155 related articles for article (PubMed ID: 25888717)
1. Response.
Heijnsdijk EA; de Koning HJ
J Natl Cancer Inst; 2015 Jun; 107(6):djv111. PubMed ID: 25888717
[No Abstract] [Full Text] [Related]
2. Re: Cost-effectiveness of prostate cancer screening: a simulation study based on ERSPC data.
Noordzij MA; Blanker MH
J Natl Cancer Inst; 2015 Jun; 107(6):djv110. PubMed ID: 25888716
[No Abstract] [Full Text] [Related]
3. Re: Cost-Effectiveness of Prostate Cancer Screening: A Simulation Study Based on ERSPC Data.
Taneja SS
J Urol; 2015 Jul; 194(1):113-4. PubMed ID: 26088223
[No Abstract] [Full Text] [Related]
4. Cost-effectiveness of prostate cancer screening: a simulation study based on ERSPC data.
Heijnsdijk EA; de Carvalho TM; Auvinen A; Zappa M; Nelen V; Kwiatkowski M; Villers A; Páez A; Moss SM; Tammela TL; Recker F; Denis L; Carlsson SV; Wever EM; Bangma CH; Schröder FH; Roobol MJ; Hugosson J; de Koning HJ
J Natl Cancer Inst; 2015 Jan; 107(1):366. PubMed ID: 25505238
[TBL] [Abstract][Full Text] [Related]
5. Re: prostate cancer screening in the randomized prostate, lung, colorectal, and ovarian cancer screening trial: mortality results after 13 years of follow-up.
Braillon A; Dubois G
J Natl Cancer Inst; 2012 May; 104(10):793; author reply 793-4. PubMed ID: 22491229
[No Abstract] [Full Text] [Related]
6. Cost-effectiveness analysis of PSA-based mass screening: Evidence from a randomised controlled trial combined with register data.
Booth N; Rissanen P; Tammela TLJ; Kujala P; Stenman UH; Taari K; Talala K; Auvinen A
PLoS One; 2019; 14(11):e0224479. PubMed ID: 31689326
[TBL] [Abstract][Full Text] [Related]
7. Further evidence that prostate-specific antigen screening reduces prostate cancer mortality.
Stampfer MJ; Jahn JL; Gann PH
J Natl Cancer Inst; 2014 Mar; 106(3):dju026. PubMed ID: 24610908
[No Abstract] [Full Text] [Related]
8. Response.
Stattin P; Carlsson S; Jonsson H
J Natl Cancer Inst; 2014 Oct; 106(10):. PubMed ID: 25269489
[No Abstract] [Full Text] [Related]
9. Screening for prostate cancer: time to put all the data on the table.
Haines IE; Ablin RJ; Miklos GL
BMJ; 2016 May; 353():i2574. PubMed ID: 27226459
[No Abstract] [Full Text] [Related]
10. Prostate-Specific Antigen (PSA)-Based Population Screening for Prostate Cancer: An Economic Analysis.
Tawfik A
Ont Health Technol Assess Ser; 2015; 15(11):1-37. PubMed ID: 26366237
[TBL] [Abstract][Full Text] [Related]
11. Response.
Haines IE; Gabor Miklos GL
J Natl Cancer Inst; 2014 Feb; 106(2):djt433. PubMed ID: 24399848
[No Abstract] [Full Text] [Related]
12. RE: Prostate-specific antigen screening trials and prostate cancer deaths: the androgen deprivation connection.
Carlsson S; Roobol MJ; Schröder FH; Hugosson J; Auvinen A
J Natl Cancer Inst; 2014 Apr; 106(5):. PubMed ID: 24771874
[No Abstract] [Full Text] [Related]
13. Re: Prostate-specific antigen screening trials and prostate cancer deaths: the androgen deprivation connection.
Walsh PC
J Natl Cancer Inst; 2014 Feb; 106(2):djt432. PubMed ID: 24399847
[No Abstract] [Full Text] [Related]
14. Prostate cancer screening: biases and the need for consensus.
Brawley OW
J Natl Cancer Inst; 2013 Oct; 105(20):1522-4. PubMed ID: 24092919
[No Abstract] [Full Text] [Related]
15. American Urological Association (AUA) guideline on prostate cancer detection: process and rationale.
Carter HB
BJU Int; 2013 Sep; 112(5):543-7. PubMed ID: 23924423
[TBL] [Abstract][Full Text] [Related]
16. [Prostate cancer screening: no proof of the benefit].
Laplanche A; Hill C
Presse Med; 2009 Oct; 38(10):1393-5. PubMed ID: 19647979
[No Abstract] [Full Text] [Related]
17. [Screening for prostate cancer using prostate-specific antigen (PSA) : A commentary on a systematic review and meta-analysis].
Borkowetz A
Urologe A; 2019 Aug; 58(8):925-928. PubMed ID: 31240375
[No Abstract] [Full Text] [Related]
18. Re: prostate cancer mortality in areas with high and low prostate cancer incidence.
Pinsky PF
J Natl Cancer Inst; 2014 Oct; 106(10):. PubMed ID: 25269488
[No Abstract] [Full Text] [Related]
19. Re: Public knowledge of benefits of breast and prostate cancer screening in Europe.
Brenner H; Heywang-Köbrunner S; Becker N
J Natl Cancer Inst; 2010 Mar; 102(5):356; author reply 356-7. PubMed ID: 20075365
[No Abstract] [Full Text] [Related]
20. Reducing prostate cancer deaths: unsupported speculation about the androgen deprivation hypothesis.
Carter HB
Eur Urol; 2014 Dec; 66(6):973-4. PubMed ID: 25018035
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
